Novo Nordisk Files Q1 2025 Report
Ticker: NONOF · Form: 6-K · Filed: May 7, 2025 · CIK: 353278
Sentiment: neutral
Topics: financial-report, quarterly-results, pharmaceuticals
TL;DR
Novo Nordisk dropped its Q1 2025 report on 5/7/25.
AI Summary
Novo Nordisk A/S filed a Form 6-K on May 7, 2025, reporting its first quarter results for the period ending March 31, 2025. The company, headquartered in Bagsvaerd, Denmark, is a pharmaceutical preparations company.
Why It Matters
This filing provides investors with the latest financial performance data for Novo Nordisk, a major player in the pharmaceutical industry, impacting its stock valuation and investor confidence.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) providing quarterly results, which is standard for publicly traded companies.
Key Players & Entities
- NOVO NORDISK A S (company) — Registrant
- 0001628280-25-022877 (filing_id) — Accession Number
- 20250331 (date) — Conformed Period of Report
- 20250507 (date) — Filed as of Date
- Bagsvaerd Denmark (location) — Company Headquarters
FAQ
What is the filing type and date?
The filing type is a Form 6-K, filed on May 7, 2025.
What period does this report cover?
The conformed period of report is March 31, 2025.
Where is Novo Nordisk A/S headquartered?
Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
What is the company's Standard Industrial Classification code?
The company's Standard Industrial Classification code is 2834, Pharmaceutical Preparations.
Does Novo Nordisk file annual reports under Form 20-F or 40-F?
Novo Nordisk indicates it files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 7, 2025 regarding NOVO NORDISK A S (NONOF).